Cargando…

Predicting roles of IL-27 and IL-32 in determining the severity and outcome of COVID-19

OBJECTIVE: Immune changes play fundamental roles in the pathogenesis and severity of coronavirus disease 2019 (COVID-19). Previous studies have revealed alterations in immune responses of patients with non-severe and severe COVID-19. Therefore, this study investigated whether interleukin-27 (IL-27)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamani, Batool, Najafizadeh, Maedeh, Motedayyen, Hossein, Arefnezhad, Reza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Inflammatory Mediators in COVID-19 and Other Diseases - Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742516/ https://www.ncbi.nlm.nih.gov/pubmed/36476070 http://dx.doi.org/10.1177/03946320221145827

Ejemplares similares

Immune system changes during COVID-19 recovery play key role in determining disease severity
por: Fathi, Farshid, et al.
Publicado: (2020)

SARS-CoV-2 (COVID-19) and audio-vestibular disorders
por: Fancello, Virginia, et al.
Publicado: (2021)

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance
por: Aschenbrenner, Dominik, et al.
Publicado: (2021)

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
por: Galván-Román, José María, et al.
Publicado: (2021)

C1q/TNF-related protein-1: Potential biomarker for early diagnosis of autism spectrum disorder
por: Raeisy, Hamed, et al.
Publicado: (2022)

Roles of C-reactive protein polymorphisms and life event changes on cognitive function in bipolar patients receiving valproate
por: Chen, Po See, et al.
Publicado: (2022)

Clinical and hematological characteristics of 300 COVID-19 patients in Erbil, Kurdistan Region, Iraq
por: Hwaiz, Rundk Ahmad, et al.
Publicado: (2022)

COVID-19 and erythrocrine function: The roller coaster and danger
por: Al-kuraishy, Hayder M, et al.
Publicado: (2022)

Laboratory biomarker predictors for disease progression and outcome among Egyptian COVID-19 patients
por: Fathalla, Lamiaa A, et al.
Publicado: (2022)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
por: Herold, Tobias, et al.
Publicado: (2020)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment
por: Bertoni, Arinna, et al.
Publicado: (2022)

IL-6–based mortality risk model for hospitalized patients with COVID-19
por: Laguna-Goya, Rocio, et al.
Publicado: (2020)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts
por: Utrero-Rico, Alberto, et al.
Publicado: (2021)

IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells
por: Ullrich, Karen Anne-Marie, et al.
Publicado: (2023)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department
por: Van Singer, Mathias, et al.
Publicado: (2021)

The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
por: Copaescu, Ana, et al.
Publicado: (2020)

Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells
por: Hsieh, Li-En, et al.
Publicado: (2022)

Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6
por: Karadaş, Ömer, et al.
Publicado: (2021)

Chosen laboratory markers as a determinant of COVID-19 severity
por: Navolokin, Ihor, et al.
Publicado: (2022)

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
por: Xu, Jun, et al.
Publicado: (2023)

Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis
por: Symons, Rebecca A, et al.
Publicado: (2022)

Improvement of inflammatory dermatoses severity and quality of life in patients treated with a betamethasone valerate plaster (LIBERE study)
por: Maccari, Francois
Publicado: (2016)

Myosteatosis predicting risk of transition to severe COVID-19 infection
por: Yi, Xiaoping, et al.
Publicado: (2022)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Faecal metabolome and its determinants in inflammatory bowel disease
por: Vich Vila, Arnau, et al.
Publicado: (2023)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Therapeutic Aspects of Mesenchymal Stem Cell-Based Cell Therapy with a Focus on Human Amniotic Epithelial Cells in Multiple Sclerosis: A Mechanistic Review
por: ArefNezhad, Reza, et al.
Publicado: (2021)

Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19
por: Abolhassani, Hassan, et al.
Publicado: (2022)

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
por: Yang, Yang, et al.
Publicado: (2020)

Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study
por: Gude-Sampedro, Francisco, et al.
Publicado: (2020)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies
por: Calméjane, Louis, et al.
Publicado: (2023)

Admission Hyperglycemia in Non-diabetics Predicts Mortality and Disease Severity in COVID-19: a Pooled Analysis and Meta-summary of Literature
por: Sachdeva, Sonali, et al.
Publicado: (2020)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
por: Rutgeerts, Paul J, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cna2fc8oiv0skl4s9adb7jfn0s